FDA Panel Supports Adding BPC-157 to Compounding List

According to ABC News, a Food and Drug Administration (FDA) advisory committee has voted to add BPC-157, a popular peptide, to a drug compounding list. This decision is a step toward making BPC-157 legally available for prescription, although it still requires final approval from the FDA.

The Pharmacy Compounding Advisory Committee voted 8-6 in favor of this move, with one member abstaining. While this vote is non-binding, it suggests a growing interest in alternative regulatory pathways for substances like peptides, which are amino acid chains smaller than proteins. These compounds are often marketed online for benefits such as gut healing and muscle building, but human clinical data supporting their safety and effectiveness is limited.

The committee's discussions highlighted differing views. Those in favor of the decision believe the risks are minimal, while opponents express concern about potential safety issues and the lack of rigorous evaluation compared to FDA-approved drugs.

For older adults, this development may be of interest if you're exploring new treatment options. However, it's important to consult with your healthcare provider to understand the potential benefits and risks before considering any new compound.